Nurix Therapeutics, Inc.

NRIX

US67080M1036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
12.36 ^USD	0.00%		-9.05%	+19.77%

Apr. 12	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
Apr. 12	Sector Update: Health Care	MT

Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to S&P Biotechnology Select Industry Index

March 17, 2024

Latest news about Nurix Therapeutics, Inc.

Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 12	MT
Sector Update: Health Care	Apr. 12	MT
North American Morning Briefing : Big Banks Kick off Earnings Season	Apr. 12	DJ
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	Apr. 12	MT
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours	Apr. 11	MT
Baird Adjusts Price Target on Nurix Therapeutics to $25 From $24, Maintains Outperform Rating	Apr. 11	MT
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier	Apr. 11	MT
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 10	CI
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M	Apr. 10	MT
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	Apr. 09	DJ
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	Apr. 09	CI
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	Apr. 09	MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	Apr. 09	CI
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years	Apr. 02	MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration	Apr. 02	DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences	Apr. 02	CI
Nurix Therapeutics, Inc. Presents the Discovery and Chemical Structure of First-In-Class CBL-B Inhibitor NX-1607 at the American Chemical Society Meeting	Mar. 20	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Nurix Therapeutics Says US FDA Lifts Partial Clinical Hold on Phase 1 Trial of NX-2127	Mar. 11	MT
Nurix Therapeutics : FDA Lifts Partial Clinical Hold on NX-2127 Study	Mar. 11	DJ
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial	Mar. 11	CI
Morgan Stanley Adjusts Nurix Therapeutics' Price Target to $10 From $9, Keeps Equalweight Rating	Feb. 26	MT
HC Wainwright Cuts Nurix Therapeutics Price Target to $19 From $35, Maintains Buy Rating	Feb. 20	MT
RBC Cuts Price Target on Nurix Therapeutics to $22 From $24, Keeps Outperform, Speculative Risk	Feb. 16	MT

Chart Nurix Therapeutics, Inc.

Duration

Period

More charts

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Nurix Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.36 USD

Average target price

25.09 USD

Spread / Average Target

+103.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NURIX THERAPEUTICS, INC.	+19.77%	733M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs